Precision medicine, as defined by individualized therapeutic targeting of oncogenic mutations, has had limited success in treating Multiple Myeloma (MM). FISH cytogenetics and next generation sequencing (NGS) have led to attempts of subtype classification, however this minimally affects treatment decisions to date. Additionally, identifying accurate and clinically available biomarkers to signal drug sensitivities has proven difficult for MM. This review discusses the previous attempts at precision medicine in MM with an in-depth focus on BCL2 inhibition. Next, select ongoing studies are reviewed including discussing relevant biomarkers being utilized in current clinical trials. Finally, we discuss potential future directions for a promising treatment approach.